CORONA Remedies board met and approved Q1 financial results. Revenue grew 21.9% YoY to ₹422.4 Cr, PAT up 30.1% YoY to ₹60.1 Cr. The company inaugurated an EU-GMP approved Female Hormone Facility and integrated the Wokadine brand.
CORONA Remedies commences commercial production at its EU-GMP approved Women's Hormone facility in Bhayla, Ahmedabad. The facility has a capacity of 194 million tablets/capsules and 1.5 million ointments/gels annually, boosting in-house hormone production by ~20%.
CORONA Remedies Limited is holding its 22nd Annual General Meeting and has made its Annual Report for FY2025-26 available online for members. The board has proposed a dividend of ₹10 per equity share for FY2026.
CORONA Remedies board has proposed a final dividend of ₹10 per share for FY26. Shareholders are informed about tax deduction at source (TDS) on dividend payments, requiring updated PAN and KYC details with Depository Participants.
CORONA Remedies Limited's annual secretarial compliance report confirms adherence to all statutory provisions and corporate practices. The company has maintained a functional website and timely disclosures. No actions were taken by SEBI or stock exchanges against the company.
